Market Cap 139.74M
Revenue (ttm) 38.63M
Net Income (ttm) -41.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -106.29%
Debt to Equity Ratio 0.00
Volume 878,600
Avg Vol 1,012,696
Day's Range N/A - N/A
Shares Out 106.67M
Stochastic %K 6%
Beta 1.22
Analysts Strong Sell
Price Target $7.00

Company Profile

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications;...

Industry: Medical Devices
Sector: Healthcare
Phone: 301 944 1700
Address:
9713 Key West Avenue, Suite 400, Rockville, United States
BeefStewart
BeefStewart Jan. 15 at 9:07 PM
$MXCT Why is this such a hated stock?
0 · Reply
BeefStewart
BeefStewart Jan. 15 at 9:01 PM
$MXCT 🫣
0 · Reply
BeefStewart
BeefStewart Jan. 15 at 7:39 PM
$MXCT With 150m+ in cash, a buyer is basically getting an instant rebate if they purchase the company. The *right* buyer would potentially instantly be able to find operating efficiencies via integration of MaxCyte’s business into their own, which could potentially lower the already greatly reduced cashburn. I would think a lowball takeover bid between 2.50-3 is realistic, even though I think $4.X is possible and not unrealistic, give that it reflects an enterprise value of around 277 (assuming a buyout occurs when the company has 150m remaining in the bank - 5.6m less than what they ended the year with, according to the preliminary q4 update). Just my 2 cents. Not advice.
0 · Reply
BeefStewart
BeefStewart Jan. 15 at 4:29 PM
$MXCT I believe this could be worth 4 dollars per share in the medium term.
0 · Reply
BeefStewart
BeefStewart Jan. 15 at 4:16 PM
$MXCT I'm happy for anyone who bought yesterday afternoon ❤️
0 · Reply
BeefStewart
BeefStewart Jan. 15 at 3:54 PM
0 · Reply
Kazooper
Kazooper Jan. 14 at 9:14 PM
$MXCT wow I wasn't planning on dropping thousands more on here but... 1.26? You gotta be kidding me. Below all the whole board of directors insider buys? This is such a steal right now for the patient.
0 · Reply
BeefStewart
BeefStewart Jan. 14 at 9:01 PM
$MXCT More cash than the market cap. Zero debt. Long term business opportunity is obvious... I wish i had more dry powder...
1 · Reply
Bogwood
Bogwood Jan. 14 at 8:10 PM
$MXCT Anyone know how much their top line will be impacted by the lay offs? I don't understand how this latest restructuring can _still_ only get them to a $15M annual burn
0 · Reply
BeefStewart
BeefStewart Jan. 14 at 6:16 PM
$MXCT being wrong really sucks
1 · Reply
Latest News on MXCT
MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 7:11 PM EST - 2 months ago

MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript


MaxCyte Announces Planned CFO Transition in 2026

Nov 12, 2025, 4:08 PM EST - 2 months ago

MaxCyte Announces Planned CFO Transition in 2026


MaxCyte, Inc. (MXCT) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 3:45 AM EDT - 5 months ago

MaxCyte, Inc. (MXCT) Q2 2025 Earnings Call Transcript


MaxCyte Signs Platform License Agreement with Adicet Bio

Aug 4, 2025, 8:05 AM EDT - 5 months ago

MaxCyte Signs Platform License Agreement with Adicet Bio


MaxCyte, Inc. (MXCT) Q1 2025 Earnings Call Transcript

May 10, 2025, 11:57 PM EDT - 8 months ago

MaxCyte, Inc. (MXCT) Q1 2025 Earnings Call Transcript


MaxCyte, Inc. (MXCT) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 7:52 PM EDT - 11 months ago

MaxCyte, Inc. (MXCT) Q4 2024 Earnings Call Transcript


MaxCyte Announces Retirement of Board Member Art Mandell

Dec 23, 2024, 2:00 AM EST - 1 year ago

MaxCyte Announces Retirement of Board Member Art Mandell


MaxCyte, Inc. (MXCT) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 10:01 PM EST - 1 year ago

MaxCyte, Inc. (MXCT) Q3 2024 Earnings Call Transcript


MaxCyte to Participate in Two Upcoming Investor Conferences

Oct 31, 2024, 8:05 AM EDT - 1 year ago

MaxCyte to Participate in Two Upcoming Investor Conferences


MaxCyte Appoints Cynthia Collins to its Board of Directors

Oct 15, 2024, 8:05 AM EDT - 1 year ago

MaxCyte Appoints Cynthia Collins to its Board of Directors


Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up

Oct 4, 2024, 5:19 PM EDT - 1 year ago

Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up


MaxCyte, Inc. (MXCT) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 12:09 AM EDT - 1 year ago

MaxCyte, Inc. (MXCT) Q2 2024 Earnings Call Transcript


MaxCyte, Inc. (MXCT) Q1 2024 Earnings Call Transcript

May 11, 2024, 8:35 AM EDT - 1 year ago

MaxCyte, Inc. (MXCT) Q1 2024 Earnings Call Transcript


MaxCyte, Inc. (MXCT) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 10:40 PM EDT - 2 years ago

MaxCyte, Inc. (MXCT) Q4 2023 Earnings Call Transcript


BeefStewart
BeefStewart Jan. 15 at 9:07 PM
$MXCT Why is this such a hated stock?
0 · Reply
BeefStewart
BeefStewart Jan. 15 at 9:01 PM
$MXCT 🫣
0 · Reply
BeefStewart
BeefStewart Jan. 15 at 7:39 PM
$MXCT With 150m+ in cash, a buyer is basically getting an instant rebate if they purchase the company. The *right* buyer would potentially instantly be able to find operating efficiencies via integration of MaxCyte’s business into their own, which could potentially lower the already greatly reduced cashburn. I would think a lowball takeover bid between 2.50-3 is realistic, even though I think $4.X is possible and not unrealistic, give that it reflects an enterprise value of around 277 (assuming a buyout occurs when the company has 150m remaining in the bank - 5.6m less than what they ended the year with, according to the preliminary q4 update). Just my 2 cents. Not advice.
0 · Reply
BeefStewart
BeefStewart Jan. 15 at 4:29 PM
$MXCT I believe this could be worth 4 dollars per share in the medium term.
0 · Reply
BeefStewart
BeefStewart Jan. 15 at 4:16 PM
$MXCT I'm happy for anyone who bought yesterday afternoon ❤️
0 · Reply
BeefStewart
BeefStewart Jan. 15 at 3:54 PM
0 · Reply
Kazooper
Kazooper Jan. 14 at 9:14 PM
$MXCT wow I wasn't planning on dropping thousands more on here but... 1.26? You gotta be kidding me. Below all the whole board of directors insider buys? This is such a steal right now for the patient.
0 · Reply
BeefStewart
BeefStewart Jan. 14 at 9:01 PM
$MXCT More cash than the market cap. Zero debt. Long term business opportunity is obvious... I wish i had more dry powder...
1 · Reply
Bogwood
Bogwood Jan. 14 at 8:10 PM
$MXCT Anyone know how much their top line will be impacted by the lay offs? I don't understand how this latest restructuring can _still_ only get them to a $15M annual burn
0 · Reply
BeefStewart
BeefStewart Jan. 14 at 6:16 PM
$MXCT being wrong really sucks
1 · Reply
BeefStewart
BeefStewart Jan. 14 at 5:17 PM
$MXCT it feels like there is no bottom
0 · Reply
CH_Expat
CH_Expat Jan. 13 at 6:04 PM
$MXCT Back in.
0 · Reply
BeefStewart
BeefStewart Jan. 13 at 5:36 PM
$MXCT Trading below the low end estimate of 2027 cash... This is insane.
0 · Reply
RocketThief
RocketThief Jan. 13 at 3:18 PM
$MXCT adding at these levels. <$0 EV offers a great swing around core opportunity
0 · Reply
BeefStewart
BeefStewart Jan. 13 at 8:25 AM
$MXCT http://bit.ly/4pFadkn "-CASGEVY® launch acceleration continues, supporting multi-billion-dollar potential-" $CRSP and $VRTX sales of Casgevy = royalties for MaxCyte. Hoping to see Casgevy sales accelerate significantly in 2026.
0 · Reply
BeefStewart
BeefStewart Jan. 12 at 3:47 PM
$MXCT Rough start to the day, but they have slightly more cash on hand than the high end of what was expected. They have a lot of options with that much cash, including a modest share buyback in my opinion...
0 · Reply
BeefStewart
BeefStewart Jan. 9 at 4:05 PM
0 · Reply
BeefStewart
BeefStewart Jan. 8 at 8:16 PM
$MXCT Anyone else still here? I hear an echo... 🥺🫣😬🥹
1 · Reply
BeefStewart
BeefStewart Jan. 6 at 7:38 PM
$MXCT It's easy to lose hope when the stock languishes; yet the fundamentals remain unchanged. Management has demonstrated that they are able to continually sign new SPLs throughout the year (3-5 annually is what they project, and they met that target in 2025), and they already have multiple shots on the same goals as their SPLs overlap, which provides redundancy in the event of trials not reaching commercialization. With Casgevy commercialized and sales accelerating, they have provided proof that their business model is viable as royalties are starting to trickle in, while milestone payments, tool sales, and equipment leasing (for clinical trial research) keep the lights on for now, and should only get larger beginning in H2 of this year. Hoping for the best, and open to any criticism/opposing perspectives as well! Great luck everyone! Beef 🥩
0 · Reply
BeefStewart
BeefStewart Jan. 6 at 7:26 PM
$MXCT This company has something very value besides its intellectual property: runway! They have cash runway for 10-15 years, based on their projected 2026 cash burn of 10-15 million, assuming little or no growth and only 150M left in the bank by end of 2025. They expect to have around 152-155M in the bank as of end of December 2025, so even if they are on the low end of that, they have plenty of time to make great things happen here. If Casgevy sales reach 1B annually in 2026 or 2027, that is $10M in annual royalties for MXCT, which is tremendous given their already reduced opex. I remain very bullish at these levels.
0 · Reply
BeefStewart
BeefStewart Jan. 6 at 6:16 PM
$MXCT added more
0 · Reply
BeefStewart
BeefStewart Jan. 5 at 9:24 PM
$MXCT another flat day... interesting!
0 · Reply